Published in Gene Therapy Weekly, May 16th, 2002
The initial results of a double-blind, randomized trial of 79 patients participating in the multicenter angiogenic gene therapy (AGENT) trial have indicated viral-based therapy delivering genes for fibroblast growth factor (FGF) directly to the heart improves exercise time on treadmill tests in patients with angina.
The study cohort included angina patients categorized as class 2 or 3 under the Canadian Cardiovascular Society classification system. Cindy L. Grines and colleagues at William Beaumont...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.